Cargando…
The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis
Background: Despite meticulous surgery for non-small cell lung cancer (NSCLC), relapse is as high as 70% at 5 years. Many institutions do not conduct reflexive molecular testing on early stage specimens, although targeted gene therapy may extend life by years in the event of recurrence. This ultimat...
Autores principales: | McGuire, Anna L., McConechy, Melissa K., Melosky, Barb L., English, John C., Choi, James J., Peng, Defen, Yee, John, Furman, Benjamin L. S., Aguirre Hernandez, Rosalia, Feijao, Pedro, Mulder, David, Hughesman, Curtis, Yip, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031556/ https://www.ncbi.nlm.nih.gov/pubmed/35448189 http://dx.doi.org/10.3390/curroncol29040215 |
Ejemplares similares
-
Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer
por: McGuire, Anna L, et al.
Publicado: (2020) -
Acute organ injury is associated with alterations in the cell-free plasma transcriptome
por: Boyd, John H, et al.
Publicado: (2014) -
Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
por: Banyi, Norbert, et al.
Publicado: (2022) -
Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice
por: Indrambarya, Toonchai, et al.
Publicado: (2009) -
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study
por: Hilzenrat, Roy Avraham, et al.
Publicado: (2022)